Pharmion Doubles Vidaza Sales Guidance For Second Half 2004
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is raising its previous guidance of $20 mil.-$27 mil. due to greater than anticipated sales of the myelodysplastic syndromes treatment in the three months since launch.